Updated
Updated · MarketWatch · Apr 28Inovio Pharmaceuticals Inc. stock slides 1.71 percent and underperforms competitors
5 articles · Updated · MarketWatch · Apr 28
- Shares closed at $1.15, snapping a two-day winning streak, with trading volume at 1.1 million, below average.
- The stock remains 61.40% below its 52-week high of $2.98, reached on September 9th, 2025.
- Inovio's performance contrasted with Johnson & Johnson's 1.09% gain and Pfizer's 1.16% decline during a broadly negative market session.
Inovio's new drug faces an approved rival. Does its second-year clinical data give it a competitive edge? Can Inovio's new cancer drug partnership de-risk the company from its dependence on a single product? With cash reserves dwindling, how will Inovio survive if its lead drug approval is delayed past October? Is the recent 'hammer' chart pattern a sign of a real turnaround for Inovio or a classic bull trap? Facing an FDA challenge on its accelerated approval path, what is Inovio's Plan B for its lead drug? Why do analysts predict a 500% stock surge for a company facing lawsuits and a financial crisis?